Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

IRB Advisor

RSS  

Articles

  • Special Report: Regulations and Rules--Are We Heading in the Right Direction?

    IRB Advisor asked IRB and human subjects protection experts from across the nation to discuss the state of human subjects protection regulations and how IRBs are interpreting federal requirements. This article, which is the last in the three-part series, will discuss investigator certification and training.
  • On-line education is becoming standard

    At institutions across the country, research administrators now are using Internet-based or local computer software modules to facilitate annual education in human subjects protections for investigators and IRB members.
  • Bill for national trials registry on the table

    A federally funded national clinical trials registry may soon be a reality if the American Medical Association (AMA) and several Democratic senators have their way.
  • News Briefs

    Senate passes BioShield; $5.6B slated for industry; FDA initiative seeks to speed up approvals; OHRP to require IRB registration.
  • Lawsuit challenges use of blood samples

    The Havasupai Indian tribe of northwestern Arizona, and some of its individual members, have filed two federal lawsuits seeking a total of $75 million in damages against Arizona State University (ASU), the Arizona Board of Regents, and three university researchers, claiming that blood samples taken from tribe members as part of a diabetes study were destroyed, lost, or used in studies of schizophrenia, inbreeding, and population migration without the donors consent.
  • Spotlight on Compliance, Experimental devices need FDA approval

    A report in the March 25 Philadelphia Inquirer regarding the use of experimental treatment on an infant in connection with a heart repair highlights a series of issues related to both the use of devices not approved by the FDA and, in turn, their use on minors, including infants.
  • Developing and assessing institutional conflict of interest policy can be tricky

    When the National Institutes of Health (NIH) recently became the target of intense public criticism and scrutiny over potential conflicts of interest (COI) among NIH directors and staff and clinical trials, it became apparent to the research world that this is an issue that could be a problem for any institution. The best prevention strategy is to be proactive by having policies, procedures, and possibly a special committee that reviews COIs, experts say.
  • As international research trials increase, new problems crop up

    As the number of international research protocols increase, the problems faced by reviewing IRBs increase. International research is taking more and more IRB time, says Howard Guenther, PhD, MBA, associate vice chancellor for research and interim executive secretary of the Institutional Review Board at the University of Illinois at Urbana-Champaign.
  • NIH changes COI policy in response to scrutiny

    IRBs and institutions might take away two important thoughts from the NIHs recent experience: First, it doesnt take more than the appearance of a conflict to harm ones reputation. Secondly, some of the measures NIH has taken in response might guide institutions in their own conflict of interest (COI) policy-making.
  • Research on prisoners requires OHRP approval

    The regulations regarding the use of prisoners in research have not changed since 1978, but the research communitys awareness and perception of these have changed. As a result its a good idea for IRBs to update policies regarding such research.